Gastroesophageal Adenocarcinoma Recruiting Phase 1 / 2 Trials for Nivolumab (DB09035)

IndicationStatusPhase
DBCOND0030813 (Gastroesophageal Adenocarcinoma)Recruiting1 / 2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03639714A Study of a Personalized Neoantigen Cancer VaccineTreatment